Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Liabilities and Shareholders Equity (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $366.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 40.49% to $366.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 1.31% decrease, with the full-year FY2025 number at $366.3 million, up 40.49% from a year prior.
  • Liabilities and Shareholders Equity was $366.3 million for Q4 2025 at Fulcrum Therapeutics, up from $214.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $366.3 million in Q4 2025 to a low of $137.9 million in Q2 2021.
  • A 5-year average of $247.6 million and a median of $245.2 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: surged 81.36% in 2021, then fell 27.57% in 2024.
  • Fulcrum Therapeutics' Liabilities and Shareholders Equity stood at $235.0 million in 2021, then decreased by 3.54% to $226.7 million in 2022, then grew by 13.68% to $257.7 million in 2023, then increased by 1.17% to $260.7 million in 2024, then skyrocketed by 40.49% to $366.3 million in 2025.
  • Per Business Quant, the three most recent readings for FULC's Liabilities and Shareholders Equity are $366.3 million (Q4 2025), $214.9 million (Q3 2025), and $228.8 million (Q2 2025).